{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-182222","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.076215+00:00","generated_at":"2026-05-17T11:52:43.603649+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025","bullets":["Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.","Adaptive expects $33.7M non-cash revenue in H2 2025 from remaining amortization of cash consideration.","Company released from exclusivity obligations in oncology cell therapies.","Ongoing Immune Medicine programs: digital TCR-antigen models, T-cell depletion in autoimmunity, FY2025 cash burn target $25-30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-182222","json":"https://secwatch.observer/filing/0001193125-25-182222.json","markdown":"https://secwatch.observer/filing/0001193125-25-182222.md","text":"https://secwatch.observer/filing/0001193125-25-182222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/0001193125-25-182222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/d59058d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:52:43.603649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}